The Visit That Hadn’t Changed in 20 Years

Karen was 46 and prided herself on staying on top of her health. Annual mammogram, check. Pap smear, check. Cholesterol, check. She walked three miles a day, ate salads for lunch, took a multivitamin, and hadn’t missed a doctor’s appointment in a decade.

So when she woke up one morning and couldn’t remember the word for “refrigerator,” she figured she was just tired. When her periods started coming every two weeks — then not at all for three months — she assumed stress. When she lay awake until 2 a.m. with her heart pounding for no reason, she Googled “anxiety in your forties” and ordered magnesium gummies.

What Karen didn’t know — because nobody told her — was that she was in perimenopause. That her bone density had been quietly declining for five years without a single scan. That the “heart pounding” deserved a cardiovascular workup, not a supplement. That her mother’s colon cancer diagnosis three years ago should have triggered a colonoscopy referral that never happened. That the antidepressant her primary care doctor prescribed for her insomnia was actually masking symptoms that had a hormonal explanation.

Karen’s doctors were all competent. Her visits were all thorough — by the standards of a 25-year-old patient. But Karen wasn’t 25 anymore, and her medical care hadn’t caught up.

The Decade Nobody Prepares You For

Your forties are when the math changes.

Cancer risk rises. Cardiovascular disease — the number one killer of women, and it’s not even close — starts its slow climb. Bone loss accelerates, especially in the years surrounding menopause. Metabolic shifts make weight management genuinely harder (no, it’s not your imagination). Thyroid function can quietly go sideways. Autoimmune conditions that were simmering for years can surface. And the hormonal transition of perimenopause can start as early as your late thirties, bringing symptoms that mimic — and get misdiagnosed as — depression, anxiety, ADHD, thyroid disease, cardiac arrhythmia, and a dozen other conditions.

This is the decade where early detection matters most and where missed opportunities are hardest to recover from.

And yet, for millions of women, the annual visit at 44 looks almost exactly like the annual visit at 28. Same checklist. Same questions. Same fifteen minutes. Same “everything looks fine, see you next year.”

It shouldn’t.

This Post Is Your Wake-Up Call — And Your Cheat Sheet

I’ve practiced obstetrics and gynecology for over 50 years. I’ve watched women in their forties get spectacular care and I’ve watched women in their forties fall through every crack in the system. The difference almost always comes down to the same thing: whether someone asked the right questions at the right time.

This post is for every woman over 40 who suspects her medical care is still running on the script it was written when she was in her twenties. It’s for the woman who feels like something has shifted but can’t get anyone to take it seriously. It’s for the woman who wants to be proactive but doesn’t know what to ask.

These are the ten questions that should be part of every medical conversation after 40. If your doctor isn’t asking them, bring them yourself.

Subscribe to Obstetric Intelligence for more straight talk about women’s health — and share this with every woman in your life who’s hit the decade where everything changes and nobody handed her the manual.

Read more

A 2020 Cochrane review shows supervised pelvic floor training cuts that risk by 62%. Most women are told to wait and see. Most doctors have never heard about it. Here is what the evidence actually supports, and what to do about it.

A patient came to me frustrated. She had asked her prenatal team for pelvic floor physiotherapy during her third pregnancy. She was told she was being proactive. The implication was that proactive was unusual. She had also been advised to avoid sneezing where possible.

That exchange tells you everything you need to know about the state of antenatal pelvic floor care.

Subscribe now

The evidence does not support watchful waiting. It supports early, structured, supervised intervention. This post explains what the options are, what the data show, and exactly how to act on them.

How Common Is This?

Urinary incontinence during pregnancy is not a minor nuisance affecting a small subset of women. The weighted average prevalence across 36 observational studies with more than 2 million women is 41%. In the third trimester specifically, about 34 in 100 pregnant women report involuntary urine loss (1).

After delivery, the problem does not simply resolve.

At 6 weeks postpartum, prevalence is 24%.

By 12 months, it climbs back to 32% (2). Women who develop urinary incontinence during pregnancy carry a fivefold increase in odds of still having it at 7 years (OR 5.4, 95% CI 2.6 to 11.5) (3).

The pelvic floor also faces structural stress beyond the bladder. Pelvic organ prolapse, anal incontinence, and dyspareunia are all documented consequences of the mechanical and hormonal demands of pregnancy and delivery. These are not rare outcomes. Pelvic organ prolapse occurs in an estimated 14 in 100 women who deliver vaginally (4).

None of this is inevitable. The question is what can be done about it, starting now.

Paid subscribers can access the full instructions:

PAYWALL BREAK | Free readers see above. Paid subscribers continue below.

Read more

She did not have a rare disease. She had endometriosis — a condition affecting roughly 1 in 10 women worldwide. It is not obscure. It is not subtle. And yet the average time from first symptoms to confirmed diagnosis has been, for the past decade, approximately eight years.

I have been practicing obstetrics and gynecology for more than 50 years. I have seen this delay happen. I have also seen us — as a field — look away from it.

What Endometriosis Is

Endometriosis is a condition where tissue similar to the lining of the uterus grows outside the uterus — on the ovaries, fallopian tubes, bowel, bladder, and sometimes further. It causes chronic pelvic pain, painful periods, pain during sex, and in many cases, infertility.

The symptoms are not vague. Chronic pelvic pain, dysmenorrhea, and dyspareunia are present in more than 80% of women with the condition. These are not silent findings. They are the reason women come to our offices.

And yet a New Zealand study found that patients who reported being dismissed by a clinician waited an average of 9 years for a diagnosis. Those who were not dismissed waited 4.6 years. The gap is not biology. It is clinical behavior.

Subscribe now

Why the Delay Happens

The most common explanation is that period pain is normalized — by patients, by families, and by physicians. Women are told that painful periods are part of being a woman. Many believe it. Many of us have reinforced it.

There is also a diagnostic problem. The gold standard for diagnosing endometriosis is still laparoscopy — a surgical procedure. Without visible proof, the diagnosis lives in a clinical limbo. Physicians are reluctant to refer for surgery without clear imaging findings. Most endometriosis does not show on routine ultrasound. So the loop closes on itself: no proof without surgery, no surgery without proof, and the patient continues waiting.

The result is measurable suffering. Endometriosis leads to an average of 19 missed work days per year. It is among the leading causes of years lived with disability in women of reproductive age. These are not estimates. These are documented, published findings.

What Patients Are Doing Instead

They are going to Reddit at 2 a.m. They are buying books subtitled ‘what your doctor won’t tell you.’ They are spending money on supplements and elimination diets and wellness programs because someone on social media told them that medicine had failed them — and in this case, medicine had.

The r/endometriosis community has hundreds of thousands of members. The posts follow a pattern that any clinician should recognize: years of symptoms, multiple physicians, repeated reassurance that nothing is wrong, and finally — sometimes after a decade — a diagnosis that changes everything they thought about their own body.

This is not a failure of patient education. It is a failure of clinical attentiveness.

A Tool for the Conversation

I built a symptom screener — free, evidence-based, aligned with the 2026 ACOG Clinical Practice Guideline on endometriosis — to help patients organize their symptoms before a clinical visit and help clinicians see the pattern more clearly. It takes about five minutes. It produces both a patient-facing summary and a clinical differential that you can use in practice.

Use it. Share it. The link is below.

tools.obmd.com/period-pelvic-pain

If your doctor has already dismissed you — or if you are preparing for a conversation you have had before and lost — the next section is for you. I will give you the five questions that move physicians from dismissal to action, and tell you exactly when it is time to find someone else.

ObGyn Intelligence: Safety analysis, the evidence critique, and the verdict are below -- for subscribers who want the full picture.

Read more

What “Organic” Means, and Why It Is Often Misunderstood

For many women, especially during pregnancy, organic has become shorthand for safer, cleaner, and healthier. That belief is understandable and incomplete. Organic is an agricultural certification. It regulates how food is grown and, to a limited extent, processed. It restricts certain synthetic pesticides, fertilizers, genetically modified organisms, and antibiotics. It does not guarantee nutritional superiority, metabolic benefit, or protection from foodborne infection.

Organic describes production methods, not biological risk. Confusing the two can create false reassurance, which matters most in pregnancy.

What the Evidence Actually Shows

Comparative studies show that organic produce tends to have lower average pesticide residues. That may be relevant for exposure reduction. However, the same evidence consistently shows little to no clinically meaningful difference in vitamins, minerals, macronutrients, or overall nutritional value compared with conventional foods.

Sugar behaves like sugar. Refined starch behaves like refined starch. Calories still count. The body does not metabolize food differently because it carries an organic label.

The rest of this post is for paid subscribers.

Read more

What “Holistic” Actually Means

Holistic medicine is the idea that health cannot be understood by organs alone. In women’s health this matters. Fertility, pregnancy outcomes, chronic pelvic pain, and menopause symptoms are influenced by sleep, stress, nutrition, metabolic status, mental health, and social conditions. Many patients feel conventional care reacts after problems appear, while holistic care promises prevention and attention. The central insight is correct. Reproductive physiology is strongly shaped by general health and behavior long before the first prenatal visit.

The First Category: Lifestyle Medicine

The strongest component of holistic care is lifestyle medicine, and here the evidence is real.

• Preconception glycemic control in women with diabetes markedly reduces congenital malformations and pregnancy loss.

• Smoking cessation lowers risks of fetal growth restriction, placental abruption, and preterm birth.

• Appropriate gestational weight gain and physical activity reduce gestational diabetes and hypertensive disorders of pregnancy.

• Folic acid supplementation before conception prevents neural tube defects.

• Sleep quality and treatment of obstructive sleep apnea are associated with lower rates of hypertensive complications.

• Nutrition quality also matters. Diets emphasizing whole grains, plant-based foods, and unsaturated fats are associated with improved ovulatory function and better fertility outcomes in ovulatory disorders.

When holistic care means metabolic optimization and preventive behavior, it is not alternative medicine. It is earlier medicine.

The Second Category: Supportive Care and Relationship

The second category is supportive care, and again there is evidence. Cognitive behavioral therapy and structured counseling reduce perinatal depression and anxiety symptoms. Continuous labor support from a trained companion is associated with lower cesarean delivery rates, less analgesia use, and greater maternal satisfaction. Pelvic floor physical therapy improves postpartum urinary incontinence and sexual function. Lactation counseling increases breastfeeding duration. Mindfulness-based stress reduction programs show modest reductions in pregnancy-related anxiety and perceived pain. What patients often describe as “holistic” is frequently time, explanation, and continuity. Adherence improves when patients understand treatment and feel heard. The benefit is behavioral and psychological physiology interacting with medical care.

Pregnancy: Where Holistic Care Truly Helps

Pregnancy is often where interest in holistic medicine becomes strongest. Many women want to minimize medications and maximize natural health. Some of this instinct is appropriate. Nutrition, sleep, physical activity, and mental health meaningfully affect pregnancy outcomes. Regular moderate exercise during pregnancy improves glucose control and reduces the risk of gestational diabetes. Adequate protein and iron intake reduces maternal anemia. Treatment of maternal depression improves prenatal care adherence and infant outcomes. Education about fetal movement awareness increases earlier reporting of concerning symptoms. These are holistic concepts that align directly with obstetric physiology.

Pregnancy: Where Holistic Care Becomes Risky

Problems arise when holistic approaches are used as substitutes to treat serious medical conditions rather than complements.

Hypertension in pregnancy is not a lifestyle discomfort. It is a placental vascular disorder that can progress to stroke, seizure, and fetal death.

Gestational diabetes requires monitoring because fetal hyperinsulinemia changes growth patterns.

Reduced fetal movement requires evaluation because it may reflect placental insufficiency.

Herbal preparations and supplements are often assumed safe but many have unknown dosing, contamination risk, or uterine activity.

The danger is not preference for natural approaches.

The danger is delay in diagnosis.

Pregnancy complications evolve over hours and days, not philosophical frameworks.

Labor and Birth

Holistic principles can also improve labor experience when properly integrated. Mobility in labor, continuous emotional support, breathing techniques, and patient education reduce anxiety and improve perceived control. However, labor remains a physiologic stress test for the fetus. Fetal heart rate monitoring, recognition of arrest disorders, and treatment of hemorrhage exist because hypoxia and bleeding are time-dependent emergencies. A calm birth environment is beneficial. A delayed response to fetal distress is harmful. The distinction is critical.

The Third Category: Unproven or Implausible Interventions

A third component of what is often labeled holistic medicine involves interventions that are biologically implausible or unsupported by reliable evidence. Examples include treating infertility with supplements alone, attempting to prevent obstetric complications with detoxification regimens, or adjusting hormones without diagnostic indication. Some practices are merely ineffective. Others delay treatment of hypertension, infection, thyroid disease, or diabetes in pregnancy and create preventable harm. The issue is not holistic thinking itself. The issue is substituting theory for physiology. Pregnancy complications follow predictable biologic pathways, and when treatment is postponed the consequences can be immediate.

The Real Goal

Women’s health should not force a choice between attentive care and scientifically grounded care. Holistic approaches are valuable when they improve behavior, coping, prevention, and understanding. They become unsafe when they substitute for diagnosis and treatment. The future is integration with boundaries. Good care includes nutrition, mental health, and prevention, but it also recognizes that conditions like preeclampsia or ectopic pregnancy require timely medical treatment. Women do not need alternative medicine. They need complete medicine.

Last month I sat in a doctor’s waiting room and was handed a clipboard with a checklist. The form asked whether I had enough food at home, whether I was struggling to pay for utilities, whether I had a safe place to live, whether I needed help getting to appointments, and whether I felt safe in my personal relationships. Routine questions, I was told. I…

Read more

Paul Krugman published an essay this week about private credit and financial risk. He was writing about money. But I kept reading it as if it were about obstetrics.

His central argument is this: financial crises do not happen because one thing goes wrong. They happen because deregulation, institutional amnesia, opacity, and tolerance of systemic risk all accumulate quietly until the pressure exceeds what the system can hold. The cockroaches, as Jamie Dimon put it, are there long before anyone turns on the light.

Subscribe now

Replace “private credit” with “American obstetrics” and the essay reads as a near-perfect description of the maternal and neonatal mortality crisis in the United States.

The Numbers That Should Not Exist

The United States has the highest maternal mortality rate among high-income countries. Not slightly higher. Dramatically higher. In 2022, the CDC reported a maternal mortality ratio of 22.3 deaths per 100,000 live births. The comparable figures for Germany, France, and the United Kingdom were between 4 and 9. We are not talking about a gap that requires a microscope. We are talking about a gap that requires an explanation.

Neonatal mortality tells a similar story. For a country that spends more per capita on healthcare than any other nation on earth, the outcomes are not merely disappointing. They are a scandal.

How is this possible? The same way Krugman’s financial crises happen. Not one catastrophic failure. A slow accumulation of smaller ones, each normalized, each explained away, each generating its own institutional defense.

Deregulation: The Quiet Period Is Over

Krugman describes a “quiet period” in American finance, roughly 50 years after the 1930s, when regulators mostly won the arms race against risk-taking. American obstetrics had its own quiet period, roughly the middle decades of the twentieth century, when hospital birth became universal, neonatal intensive care units arrived, and maternal mortality fell by more than 90 percent.

Then the quiet period ended. The deregulation of obstetric risk did not look like financial deregulation. It looked like birth autonomy. It looked like questioning medicalization. It looked, in some iterations, like ideological opposition to hospital birth itself. The result was an expansion of out-of-hospital birth settings with variable licensure, variable training standards, and almost no mandatory adverse event reporting.

I have published on this with my colleague Frank Chervenak. Using CDC natality data, we have shown repeatedly that planned home birth in the United States carries neonatal mortality rates several times higher than planned hospital birth. This is not a fringe finding. It is consistent across years, across datasets, across analytical approaches. What it has not produced, consistently, is policy change.

Opacity: The Information Nobody Has

Krugman identifies opacity as the core structural problem with private credit. Lenders do not have to disclose their books. Borrowers do not have to disclose their finances. “In effect, private loans are treated as interactions between consenting adults,” he writes. “The rest of us have no legal right, and, presumably, no need to know what took place.”

American obstetrics operates with similar opacity when it fails. There is no national mandatory system for reporting maternal deaths and near-misses equivalent to, say, the aviation industry’s safety reporting architecture. The NTSB investigates every commercial aviation fatality and publishes its findings publicly. No comparable body exists for obstetric deaths. Most states have maternal mortality review committees, but their findings are not uniformly reported, not uniformly public, and not uniformly acted upon.

I proposed a National Obstetric and Birth Safety Investigation framework, explicitly modeled on the NTSB, precisely because this gap exists. The response from professional societies has been, to put it gently, measured. The system has no strong interest in illuminating its own failures.

Institutional Amnesia and the Upton Sinclair Principle

Krugman invokes Upton Sinclair: it is difficult to get a man to understand something when his salary depends on his not understanding it. This is, as far as I can tell, the most clinically accurate sentence in his essay.

ACOG guidelines are written by committees of physicians whose institutions, careers, and malpractice exposure are shaped by those same guidelines. The result, which I have documented using the GAAP Score instrument in a series of posts comparing ACOG against RCOG and NICE guidance, is a framework that consistently scores lower on consent specification and accountability than its British counterparts. Not because American obstetricians are worse physicians. Because the guidelines serve a different primary function.

When an institution writes its own safety rules, enforces its own safety rules, and investigates its own failures, the quiet period does not last.

The Wrong Diagnosis Is Its Own Kind of Risk

Krugman’s analysis of financial risk includes a structural observation that maps almost exactly onto my long-standing argument about American maternal mortality. The conversation in obstetrics has focused heavily on racial disparities in maternal outcomes. Black women in the United States die in childbirth at rates roughly two to three times higher than white women. That disparity is real, it is documented, and it demands a response. But here is where the analogy to financial crisis becomes uncomfortably precise: we have been treating the symptom while protecting the system that produces it.

The dominant policy response has been a push for racial equity training, implicit bias workshops, and diversity initiatives inside hospitals and medical schools. These are not worthless. But they are also not the reform. They are the equivalent of teaching individual bankers to be nicer while leaving the shadow banking system intact.

The structural driver of the disparity is insurance, not interpersonal bias. Medicaid reimburses at roughly half the rate of private insurance. The best-resourced hospitals and the most experienced physicians have no financial incentive to concentrate their practices on Medicaid patients. Poor women, who are disproportionately Black and Hispanic, are therefore disproportionately cared for in under-resourced settings by providers with fewer tools, less support staff, and higher patient loads. This is not a secret. It is a known, tolerated feature of American healthcare finance.

The solution is not to ask individual physicians to examine their biases. The solution is equal access to the same quality of care for every pregnant woman in America, regardless of her insurance status, her zip code, or her income. Every other wealthy country has figured this out. Germany has figured it out. France has figured it out. The United Kingdom has figured it out. Their maternal mortality rates are a fraction of ours, and their racial disparities in obstetric outcomes are substantially smaller, not because their physicians attended more equity seminars, but because their systems do not ration access to safe care based on ability to pay.

When we point the entire reform conversation at racial equity and away from universal access to safe obstetric care, we are not solving the problem. We are making the cockroaches harder to find. We are giving the system a story that sounds serious, requires no structural change, and leaves the financial architecture that produces the disparity completely untouched.

Cockroaches Are Not a Metaphor

Krugman’s cockroach reference is not really about cockroaches. It is about the epistemology of systemic risk. When one lender fails, others are probably holding similar assets. When one mother dies from a preventable cause, others are probably at risk from the same preventable cause. The question is whether the system has the infrastructure to learn from the first failure before the cascade begins.

Financial systems learned this lesson the hard way in 2008. American obstetrics has not yet had its 2008. The maternal mortality numbers suggest it is overdue.

My Take

Krugman ends his essay by asking how many cockroaches there are. I will end mine by noting that in obstetrics, we have been reluctant to count. Mandatory national adverse event reporting. A true NTSB-equivalent for obstetric deaths. Insurance reimbursement reform that actually aligns financial incentives with equal access and outcomes. Guideline accountability that puts patient safety above institutional protection.

None of these are new ideas. All of them face the same resistance Krugman describes in finance: the people who would implement them are the people whose salary depends on not implementing them.

Krugman is worried about 2008. I am worried about the 700 or so women who will die in American delivery rooms this year from causes that, in most other wealthy countries, would not have killed them. The financial crisis had a recovery. Those women will not.

1. Pregnancy Often Begins Before Medicine Says It Does

A miscarriage is the spontaneous loss of a pregnancy before fetal viability. Biologically it usually results from chromosomal error and cannot be prevented. Clinically we confirm pregnancy by ultrasound or laboratory criteria. Ethically, however, pregnancy frequently begins earlier.

For many women the pregnancy starts at the positive test.

The moment a second line appears, behavior changes.

Caffeine is reconsidered.

Medications are reviewed.

Exercise is modified.

Travel plans are recalculated.

Some women tell a partner immediately.

Others begin quiet planning.

The future reorganizes in minutes.

None of this depends on a visible embryo.

Medicine defines pregnancy by implantation and development. Patients often define pregnancy by anticipation. The difference is not a misunderstanding. It reflects that pregnancy is not only a physiologic state but also a narrative state. The patient has already incorporated the pregnancy into her life before she ever enters the examination room.

2. Why the Question Lands So Hard

When a loss occurs weeks later, clinicians may see an early nonviable gestation. The patient often experiences the interruption of a future already imagined.

This explains why a seemingly simple question such as “Did you feel pregnant?” can feel unsettling. Physicians hear a symptom inquiry. Patients may hear a measurement of legitimacy. If pregnancy began at the positive test, then the loss did not occur at the ultrasound. It occurred at the moment expectation collapsed.

Pregnancy exists in three domains. There is the physiologic pregnancy, defined by hormones and ultrasound findings. There is the anticipated pregnancy, defined by plans and hopes. And there is the relational pregnancy, defined by how a woman integrates the pregnancy into her identity and family. Medical care addresses the first. Grief often arises from the other two.

After the diagnosis of miscarriage, whether symptoms were strong or mild changes nothing clinically. It changes only whether the patient feels that the physician understands that a real event has taken place.

3. The Limits of “It’s Common”

Physicians frequently attempt comfort by explaining that miscarriage is common. The intention is to reduce guilt. The unintended message may be minimization.

Frequency is a population statistic. Meaning is individual. A woman does not experience her pregnancy as a percentage risk. She experiences a specific child she has already begun to imagine. When we lead with epidemiology, patients can feel that the medical facts are replacing the personal reality rather than supporting it.

The difficulty arises because clinicians are trained to solve problems. Early pregnancy loss offers little to correct. Faced with an unfixable event, physicians may gather more information or offer more explanation. Yet once the diagnosis is established, additional data rarely helps. At that point the clinical task shifts from investigation to recognition.

4. Recognition as Ethical Care

After a miscarriage, the most important professional act is not analysis but acknowledgment. A short statement often serves patients better than a careful lecture about chromosomes:
“I’m sorry. This was a real pregnancy.”

This statement does not impose beliefs about personhood. It does not overinterpret the patient’s emotions. It respects that the patient defines the meaning of the event. That is a form of autonomy often overlooked in obstetrics. Autonomy is not only choosing procedures. It is also owning the significance of one’s experience.

Our medical record will list gravidity and parity according to standardized definitions. Those definitions are necessary for clinical care. But they should not govern how we speak to patients. Medicine determines when a pregnancy ends biologically. The patient determines when it began in her life, and for many it began with the positive test.

We cannot prevent most miscarriages. We can prevent making patients feel that their pregnancy existed only as laboratory chemistry. Ethical obstetrics requires clinical precision and human recognition at the same time.

A woman sits in her gynecologist’s office. She has severe menstrual cramps that started in high school. Pain during sex that she has never mentioned because she assumed it was normal. Bloating and bowel changes every month that she chalks up to diet. She fills out a form, gets a Pap smear, and leaves. Fifteen minutes, start to finish.

She will not be diagnosed with endometriosis for another seven years.

This is not a rare story. It is the most common one. Patients with endometriosis wait an average of 4 to 11 years from the onset of symptoms to a diagnosis (1). During those years, disease can progress, new symptoms can develop, quality of life deteriorates, and healthcare costs accumulate (2). By the time these women finally get a name for what they have, many of them say the same thing: “Why didn’t anyone ask me these questions sooner?”

Subscribe now

The 10 to 15-Minute Problem

The barriers to timely endometriosis diagnosis are well documented. ACOG’s own new Clinical Practice Guideline No. 11, published in March 2026, catalogs them clearly: the variability of symptoms, the broad differential diagnosis for pelvic pain, the lack of a noninvasive diagnostic test, and the normalization of menstrual pain at both the societal and clinician level (1). Black women are significantly less likely to be diagnosed (OR 0.49, 95% CI 0.28–0.83), a disparity driven in part by persistent, racially biased beliefs about pain thresholds (3). Transgender and gender-diverse patients face additional barriers including symptom dismissal and misattribution (4).

But the guideline, while thorough in describing the problem, does not address one of its most fundamental causes: the structure of the clinical encounter itself.

The average gynecologic visit in the United States lasts under 10-15 minutes. Wmen on Medicaid are likely seeing an ObGyn in less time. They need it much more. In that window, a clinician is expected to review the chief complaint, take a focused history, perform a physical examination, discuss results, and develop a plan. For a patient with possible endometriosis, this means screening for chronic pelvic pain, dysmenorrhea, dyspareunia, dyschezia, dysuria, gastrointestinal symptoms, fatigue, and infertility, while also assessing cycle length, pain severity, family history, and the impact on quality of life (1). The data show that the likelihood of endometriosis rises dramatically as the number of symptoms increases, from an odds ratio of 5.0 with a single symptom to 84.7 with seven or more symptoms (5).

Subscribe now

No clinician can reliably capture this level of detail in a 15-minute visit. Not because they don’t care, but because the math doesn’t work.

What the New ACOG Guideline Gets Right, and Where It Falls Short

ACOG CPG No. 11 represents a meaningful shift in the approach to endometriosis diagnosis. The guideline formally recommends that a clinical diagnosis, made through symptom-based assessment, physical examination, or both, is sufficient to initiate empiric medical treatment (Strong Recommendation, Low-Quality Evidence) (1). This is an important departure from the historical reliance on surgical confirmation. For years, the message was: you need a laparoscopy to know for sure. That requirement delayed treatment, added surgical risk, and reinforced the idea that a woman’s reported symptoms were not enough.

The guideline also correctly identifies that transvaginal ultrasonography should be the initial imaging modality (Strong Recommendation, Moderate-Quality Evidence) and that biomarkers, including CA 125, are not reliable enough for diagnosis (Strong Recommendation, Low-Quality Evidence) (1). It provides a useful list of signs and symptoms suggestive of endometriosis and acknowledges the wide range of presentations, from classic dysmenorrhea to gastrointestinal symptoms, thoracic pain, and fatigue.

Subscribe now

Where the guideline falls short is in providing clinicians with a practical tool to actually implement symptom-based diagnosis in the real world.

The guideline lists the symptoms. It describes what to look for on physical examination. It presents diagnostic accuracy data for imaging modalities in meticulous detail. But it does not offer a structured screening instrument that a patient could complete before or during her visit, one that systematically captures the multi-symptom pattern that the evidence shows is so critical to identifying endometriosis.

The guideline mentions that “various validated endometriosis symptom questionnaires are available” and may be useful adjuncts (1). But it does not recommend a specific one. It does not provide one. And in the absence of a practical screening tool built into the clinical workflow, the symptom-based diagnosis the guideline recommends will continue to depend on whether the clinician has enough time, training, and inclination to ask the right questions. For many patients, particularly those who have already internalized the message that their pain is normal, the questions will never be asked.

Screening Before the Visit: A Different Approach

Subscribe now

This is why we built the ObGyn Intelligence Pelvic Pain & Period Screener, available free at tools.obmd.com.

It is, to our knowledge, the most comprehensive interactive pelvic pain and menstrual symptom screener available online. It is not a diagnostic tool. It does not replace a clinician.

What it does is something that the 15-minute visit cannot: it systematically walks a patient through every symptom domain relevant to endometriosis and other pelvic pain conditions, at the patient’s own pace, before she ever steps into the exam room.

The screener covers age, menstrual cycle characteristics, bleeding patterns, clotting and heaviness, pain severity, associated symptoms (dyspareunia, dyschezia, urinary symptoms, gastrointestinal symptoms, fatigue, mood changes), and their impact on daily life. It asks about the specific symptom combinations that the evidence shows increase the probability of endometriosis. It asks about symptoms that suggest other conditions, including adenomyosis, PCOS, fibroids, and PMDD, because women with pelvic pain deserve a complete evaluation, not a single-diagnosis screen.

At the end, the screener generates a personalized summary the patient can print, save, or bring to her appointment. Instead of trying to remember and articulate years of symptoms in 15 minutes, she walks in with a document that says: here is what I experience, here is how severe it is, and here is what the evidence says these symptoms may indicate.

The screener is free. It runs entirely in the browser. No data is stored, transmitted, or collected. Privacy by design.

Subscribe now

Why This Matters

The new ACOG guideline tells clinicians to make a clinical diagnosis based on symptoms. Good. But if the patient cannot effectively communicate her symptoms in the time available, and the clinician cannot systematically screen for them, the symptom-based approach will underperform. The guideline creates the permission to diagnose without surgery. But it does not create the mechanism to capture the information needed for that diagnosis.

A structured pre-visit screener fills that gap. It gives voice to symptoms that patients have been told are normal. It captures the multi-symptom pattern, seven or more symptoms yielding an OR of 84.7 (5), that clinicians need to see. It reduces the dependence on visit length, clinician training, and implicit bias. And it puts the patient in the position she should always have been in: as the expert on her own body, arriving with her evidence organized and ready to be heard.

Four to eleven years is too long. The ACOG guideline moves in the right direction. But guidelines alone do not diagnose patients. Tools do. Questions do. Listening does.

The screener is live at tools.obmd.com. Share it with anyone who has been told their pain is normal. After you finish it save it or print it out to take with you to your doctor.

Doctors: Share it with your patients. They can do it at home and both of you save 20-30 minures of your valuable time.

Subscribe now

References

1. Diagnosis of endometriosis. Clinical Practice Guideline No. 11. American College of Obstetricians and Gynecologists. Obstet Gynecol 2026;147:432–48.

2. Surrey E, Soliman AM, Trenz H, Blauer-Peterson C, Sluis A. Impact of endometriosis diagnostic delays on healthcare resource utilization and costs. Adv Ther 2020;37:1087–99.

3. Bougie O, Yap MI, Sikora L, Flaxman T, Singh S. Influence of race/ethnicity on prevalence and presentation of endometriosis: a systematic review and meta-analysis. BJOG 2019;126:1104–15.

4. Eder C, Roomaney R. Transgender and non-binary people’s perception of their healthcare in relation to endometriosis. Int J Transgend Health 2023;25:911–25.

5. Ballard KD, Seaman HE, de Vries CS, Wright JT. Can symptomatology help in the diagnosis of endometriosis? Findings from a national case-control study—part 1. BJOG 2008;115:1382–91.

Read more

Her doctor told her it was “just PMS.” Take some ibuprofen. Maybe try yoga.

This is the problem. Premenstrual disorders are real, treatable conditions. Yet many women suffer for years without knowing that effective treatments exist.

What Are Premenstrual Disorders?

Premenstrual disorders include a spectrum of symptoms that follow a predictable pattern: they appear during the luteal phase (the two weeks between ovulation and menstruation), then resolve within a few days of bleeding. This cyclical timing is what separates premenstrual disorders from other conditions like depression or anxiety, which persist throughout the month.

The symptoms fall into two categories.

• Mood symptoms include irritability, anger, mood swings, sudden sadness or tearfulness, sensitivity to rejection, depressed mood, and anxiety or tension.

• Physical symptoms include difficulty concentrating, fatigue, changes in appetite or food cravings, sleep problems, breast tenderness, joint or muscle pain, and bloating.

The underlying biology involves hormonal fluctuations during the menstrual cycle. Estrogen levels rise and fall in the luteal phase, which can disrupt serotonin regulation in the brain. Some women also have heightened sensitivity to allopregnanolone, a metabolite of progesterone. These hormonal shifts don’t cause problems for everyone, but for susceptible women, they trigger significant symptoms.

PMS (premenstrual syndrome) is diagnosed when any combination of these mood or physical symptoms occurs in a cyclical pattern and interferes with daily life. PMDD (premenstrual dysphoric disorder) is more severe and has specific diagnostic criteria from the DSM-5: at least 5 symptoms must be present in the week before menstruation, including at least 1 mood symptom and 1 physical symptom. These symptoms must substantially decrease or resolve within a week after menstruation begins.

Diagnosis requires tracking symptoms daily for at least two consecutive menstrual cycles using a validated tool like the Daily Record of Severity of Problems. This documentation confirms the pattern and rules out other conditions. Many women suspect they have PMDD but haven’t tracked their symptoms systematically. The tracking itself can be revealing: some women discover their symptoms don’t actually follow the luteal pattern, which points toward a different diagnosis. Others finally have proof that what they’ve experienced for years is real and has a name.The Numbers

PMS affects about 1 in 4 menstruating women. That’s common enough to be dismissed as “normal.”

PMDD (premenstrual dysphoric disorder) is different. It affects 2-5% of women and causes severe mood symptoms: irritability that destroys relationships, depression that makes work impossible, anxiety that feels unbearable. These symptoms appear in the week before menstruation and disappear within days of bleeding. The pattern is the diagnosis.

A new JAMA synopsis of ACOG guidelines, published this week, confirms what the evidence shows: we have treatments that work. The question is whether women know about them.

What Actually Works

SSRIs (antidepressants) are first-line treatment for mood symptoms. Here’s what most women don’t know: you don’t have to take them every day. Luteal-phase dosing means starting the medication at ovulation and stopping when your period begins. This works for many women and avoids the side effects of daily use.

The data: escitalopram 20mg reduced irritability by 80% compared to 30% with placebo. A 2024 Cochrane review of 12 trials found both continuous and intermittent dosing effective, with continuous slightly better.

Birth control pills containing drospirenone (brand names include Yaz and Beyaz) are the only oral contraceptives FDA-approved for PMDD. In trials, 48% of women responded to treatment versus 36% on placebo. The number needed to treat is 8, meaning for every 8 women who try it, one will benefit who wouldn’t have improved on placebo.

Cognitive behavioral therapy works too. An 8-week internet-based CBT program cut the percentage of women meeting PMDD criteria from 81% to 41%. Benefits lasted at least 3 months after treatment ended.

Most women benefit from combining approaches: lifestyle changes (exercise, sleep, stress management) plus medication or therapy.

The Real Problem

The evidence is clear. The treatments are available. So why do women suffer?

Because we’ve normalized premenstrual misery. Because “it’s just hormones” has become a way to dismiss women’s symptoms rather than treat them. Because many clinicians don’t ask, and many women don’t know they can ask.

If your symptoms interfere with your work, your relationships, or your quality of life, that’s not something you should just push through. Track your symptoms for two cycles. If the pattern fits, bring the data to your doctor.

You deserve more than “just deal with it.”

Reference: Ortiz Worthington R, Eastman LM, Alexander JT. Management of Premenstrual Disorders. JAMA. Published online February 4, 2026. doi:10.1001/jama.2025.26054

a user on Reddit’s r/Abortiondebate poses a direct question to pro-life users: If religion shouldn’t exempt patients from abortion restrictions, should it exempt physicians from liability when refusing life-saving abortions? The post notes that doctors aren’t exempt from negligence or malpractice in other contexts, and links to a Reuters article documenting that most states protect physicians who refuse abortions on religious grounds

Comment Summary (approximately 15 visible top-level comments, 50+ collapsed)

Responses split along predictable lines. Pro-choice commenters argued physicians who let patients die should face prosecution and license revocation. Pro-life responses ranged from “go to another doctor” (Dapper_Revolution_65) to explicit acceptance of maternal death as acceptable collateral damage (”It’s different when she’s pregnant” - RealNiceLady). One deleted pro-life commenter broke ranks, calling physicians who let both mother and fetus die rather than intervene a “POS.” A medical student (stonernunu) offered a visceral hypothetical about withholding resuscitation based on patients’ abortion views. Several commenters raised the critical issue of Catholic hospital acquisitions that occur without community notice, leaving patients unaware their local hospital operates under religious restrictions.

Comment Analysis

IssueCount”Go to another doctor” dismissal3Emergency scenarios prevent alternatives3Rural access/no alternatives available2Catholic hospital stealth acquisitions2Religion shouldn’t override patient safety5Hippocratic oath invoked2Explicit acceptance of maternal death2License revocation/prosecution supported4Referral obligation mentioned0

Comment

This thread exposes a critical gap in how conscience clauses function in practice versus theory. The standard justification for religious exemptions assumes a functioning referral system: the objecting physician declines but ensures the patient reaches willing care. Yet no commenter on either side mentioned this obligation.

The “go to another doctor” response reveals a fundamental misunderstanding of emergency medicine. Obstetric emergencies like placental abruption, uterine rupture, or septic abortion progress in minutes to hours. Transfer time can exceed survival time. In rural America, the nearest hospital may be the only hospital. When Catholic health systems acquire community hospitals without changing names, patients arrive expecting standard care and discover restrictions only during crisis.

The ethical framework here isn’t complex: conscientious objection in medicine has always required two conditions. First, the objection must not abandon the patient. Second, the physician must facilitate transfer to willing providers. A conscience clause that permits a physician to refuse treatment and also permits refusing referral isn’t protecting conscience. It’s permitting homicide by omission.

What’s striking is the comment accepting maternal death as categorically different “because she’s pregnant.” This reveals the unstated logic: pregnancy transforms a woman from a patient deserving standard-of-care protection into a vessel whose death is acceptable to preserve fetal life, even when both will die. That’s not a medical position. It’s a theological one masquerading as ethics.

What “Organic” Actually Means

In women’s health, “organic” is often treated as a proxy for safety, purity, or nutritional superiority. That assumption is understandable and frequently wrong. In practical terms, “organic” is an agricultural certification. It regulates how food is grown and processed, not whether it is healthy, minimally processed, or appropriate to eat often.

Organic standards generally restrict synthetic pesticides, prohibit genetically modified organisms, and limit certain fertilizers and antibiotics. They do not guarantee higher nutrient content, lower sugar, fewer calories, or better metabolic effects. Organic describes inputs and methods, not outcomes.

What the Evidence Shows, and What It Does Not

Large reviews comparing organic and conventional foods show modest differences in pesticide residues, often lower in organic produce. That finding is real and relevant, particularly for pregnant women and children, where minimizing unnecessary exposures is reasonable. However, the same reviews consistently show little to no clinically meaningful difference in macronutrients, vitamins, or minerals between organic and non-organic foods.

In other words, organic strawberries may carry fewer pesticide residues, but an organic cookie is still a cookie. The label does not transform the food’s metabolic impact.

Read more

Food labels are not written for average people. They are written for regulators, lawyers, and marketing teams. That gap matters, because women’s health and especially pregnancy are periods when vague advice like “eat clean,” “avoid processed foods,” or “choose organic” can create false confidence or unnecessary fear.

An organic label does not tell you whether a food is ultra-processed, raises blood sugar, or carries infection risk. Yet many women are expected to make daily decisions based on exactly that misunderstanding.

What women actually need is interpretation, not slogans.

Food safety in pregnancy, for example, is not about perfection or purity. It is about prioritizing real risks. Organic raw produce can carry higher Listeria risk than conventional cooked food. Unpasteurized organic milk is still unpasteurized. Some additives that look alarming on a label are clinically irrelevant, while other risks are missed entirely because they do not fit a wellness narrative. Without a framework, the loudest voices win, not the best evidence.

This is where prompts matter.

A prompt is a complete instruction to tell an LLM like ChatGPT or Claude or Gemini what it should do. In very specific ways.

A well-designed prompt does not replace medical judgment. It forces clarity. It turns a dense ingredient list into a pregnancy-specific analysis that separates chemical exposure from microbial risk, ultra-processing from farming method, and evidence from assumption. This is how physicians already think: not “good or bad,” but compared to what, for whom, at what dose, and under what conditions. Prompts allow patients to borrow that reasoning safely and transparently.

This post is about tools, not trends. If you want evidence-based clarity instead of wellness noise, subscribe. Paid subscribers get access to physician-designed prompts you can actually use, starting with food labels, where misunderstanding is common and the stakes in pregnancy are real.

Subscribe now

Below the pay line

What follows is a pregnancy-specific food label prompt (other coming soon), designed to translate ingredients into clinically meaningful information. You can copy it, paste it, and use it on any product by uploading a photo of the label. The power is not in the AI. It is in the question it is forced to answer.

Read more

Millions of women stopped their prescriptions. Physicians stopped prescribing. Within two years, hormone therapy use dropped by more than half.

Here’s what the headlines didn’t say: the average participant was 63 years old, more than a decade past menopause. Two-thirds were over 60. The average BMI was 28.5. These were not the symptomatic 51-year-old women asking their doctors about hot flashes.

The study tested one specific formulation (Prempro) in one specific population. The results were generalized to all hormone therapy in all women.

The Number: Hormone therapy prescribing dropped from 27% of postmenopausal women in 1999-2000 to 4.7% by 2020. That’s a 22-percentage-point collapse in treatment for symptoms that affect 75% to 80% of menopausal women.

What the WHI Actually Found

The WHI tested two formulations in separate trials:

Estrogen-plus-progestin (for women with a uterus): The combination of conjugated equine estrogens (0.625 mg) plus medroxyprogesterone acetate (2.5 mg) showed increased breast cancer risk and cardiovascular events in older women. This arm was stopped early.

Estrogen-alone (for women after hysterectomy): This arm continued and found something remarkable: estrogen-only therapy reduced breast cancer by 23% and showed trends toward reduced heart disease and mortality in women ages 50-59.

The media reported one story. The data told two.

The Deaths We Don’t Count

In 2013, Yale researchers published an analysis that should have been front-page news. Philip Sarrel and colleagues calculated the mortality toll of estrogen avoidance among hysterectomized women aged 50-59.

Their estimate: between 18,000 and 91,000 excess deaths over ten years. Their best point estimate was approximately 50,000 women who died prematurely because they avoided estrogen therapy after the WHI publication.

Most died of heart disease. Before 2002, more than 90% of hysterectomized women in their 50s used estrogen therapy. After 2002, that dropped to roughly 10%. The mortality difference was 13 additional deaths per 10,000 women per year.

“Estrogen avoidance has resulted in a real cost in women’s lives every year for the last 10 years,” Sarrel said, “and the deaths continue.”

The Timing That Changes Everything

The WHI’s own reanalyses revealed what researchers now call the “timing hypothesis.” When you stratify the data by age at initiation, the story transforms:

Women ages 50-59:

• Estrogen-alone: 35% reduction in coronary heart disease (HR 0.65)

• 18-year follow-up: 21% reduction in all-cause mortality (HR 0.79)

• No significant increase in stroke or breast cancer

Women ages 70-79:

• Increased cardiovascular events

• Increased stroke risk

• Different risk-benefit profile entirely

The WHI wasn’t wrong. It was misapplied.

Starting hormone therapy within 10 years of menopause, or before age 60, produces fundamentally different results than starting it at 65 in women with established cardiovascular disease.

What Professional Societies Now Say

The North American Menopause Society’s 2022 Position Statement is unequivocal:

“For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and prevention of bone loss.”

The statement adds: “The benefits of hormone therapy outweigh the risks for most healthy symptomatic women who are aged younger than 60 years and within 10 years of menopause onset.”

This isn’t controversial among menopause specialists. It hasn’t been for years.

Yet prescribing rates remain at 4-5%. The fear persists.

The Breast Cancer Question

Let me be direct about breast cancer, because this drives most of the fear.

Estrogen-alone therapy: In the WHI, estrogen-only therapy reduced breast cancer incidence by 23% and reduced breast cancer mortality. This finding has held through 20 years of follow-up.

Estrogen-plus-progestin therapy: The absolute risk increase was 8 additional breast cancer cases per 10,000 women per year. After 5 years of use, that translates to about 4 additional cases per 1,000 women.

For context, that’s similar to or less than the breast cancer risk from:

• Obesity (higher risk than combined HRT)

• Alcohol consumption (2+ drinks daily)

• Never having children

• Sedentary lifestyle

Clinical Pearl: We don’t tell women to avoid these lifestyle factors with the same urgency we tell them to avoid hormone therapy. The risk communication has been wildly disproportionate to the actual risk.

The type of progestogen matters. Micronized progesterone appears to have a more favorable breast cancer profile than synthetic progestins like medroxyprogesterone acetate (which was used in the WHI). The route matters too: transdermal estrogen avoids first-pass liver effects and shows lower clotting risk.

What We Lost

Beyond the mortality statistics, consider what millions of women lost:

Quality of life: 75-80% of menopausal women experience vasomotor symptoms. For many, hot flashes are debilitating. Night sweats destroy sleep for years. The average duration of symptoms is 7-11 years.

Bone health: Estrogen prevents bone loss. The decade after menopause is when women lose bone most rapidly. Fractures in older women carry significant mortality.

Cardiovascular protection: The cardiovascular benefit of estrogen in younger menopausal women has been obscured by results in older women who already had atherosclerosis.

Sexual function: Genitourinary syndrome of menopause affects up to 50% of postmenopausal women. Vaginal estrogen is safe and effective, yet many women believe they can’t use even local treatment.

Mental health: Emerging evidence links estrogen deficiency to depression and cognitive changes during the menopause transition.

The tragedy isn’t just that women died. It’s that millions suffered unnecessarily for two decades, and many continue to suffer today.

Bottom Line for Free Readers:

The 2002 WHI findings were misinterpreted and over-generalized. For healthy women under 60 with bothersome menopausal symptoms, hormone therapy is the most effective treatment, and the benefits typically outweigh the risks. The fear that stopped millions of women from treatment was based on data from women in their 60s and 70s, not from symptomatic women at menopause. Professional societies have moved on. It’s time for the rest of medicine, and the public, to catch up.

The Evidence in Detail

Read more

Summary

In this study in a British journal called BJOG Researchers looked for studies on how to help women after they lose a pregnancy, either from stillbirth (baby dies after 24 weeks), second-trimester miscarriage (loss between 13-24 weeks), or recurrent miscarriage (two or more losses). They searched through 18,603 studies and found only 15 that met their criteria. The quality of all these studies was poor, with small numbers of participants (14-103 women) and significant research flaws.

Read more

Ectopic Pregnancy, published in the Journal of Clinical Medicine, January 2026.

The Gist:

This narrative clinical review summarizes current evidence on the diagnosis and management of ectopic pregnancy.

Read more

The Study:

Thirty-Year Risk of Cardiovascular Disease Among Healthy Women According to Clinical Thresholds of Lipoprotein(a), published in JAMA Cardiology, January 2026.

The Gist:

This study evaluated long-term cardiovascular risk in healthy women according to baseline lipoprotein(a) levels.

Read more

The Issue, Defined Clearly

Ovarian cancer is a malignant disease of the ovaries that is usually diagnosed late, often after it has already spread beyond the pelvis. Because early symptoms are vague and there is no effective screening test, most women present with advanced-stage disease. This late diagnosis is the main reason ovarian cancer remains one of the deadliest gynecologic cancers.

That reality has not changed much, despite decades of research.

A 2025 narrative review by Caruso et al., published in JAMA, takes a hard look at where we stand today. The paper is sober, data-driven, and quietly unsettling. It confirms progress in treatment but underscores a stubborn truth: we still fail at early detection, and that failure costs lives.

What the Evidence Shows

The review makes several points that are uncomfortable but important.

First, most ovarian cancers are diagnosed at stage III or IV, when cure rates are low. Five-year survival exceeds 90 percent for stage I disease but drops to roughly 30 percent once disease is advanced. That gap is not narrowing.

Second, screening does not work. Large randomized trials evaluating CA-125 testing, transvaginal ultrasound, or combinations of the two have not reduced ovarian cancer mortality. Some increased false positives and unnecessary surgeries without improving outcomes. The review is explicit: routine screening of average-risk women causes harm without benefit.

Third, ovarian cancer is not one disease. High-grade serous carcinoma accounts for the majority of deaths and likely originates in the distal fallopian tube, not the ovary itself. Other subtypes behave differently, respond differently to therapy, and have different risk profiles. Lumping them together has slowed progress.

These points are well known individually. What the review does effectively is place them together and show how little they have changed clinical reality.

Treatment Has Improved, But Only After Diagnosis

There has been real progress in therapy. The review outlines advances in cytoreductive surgery, platinum-based chemotherapy, and targeted agents such as PARP inhibitors for women with BRCA mutations or homologous recombination deficiency.

These therapies extend progression-free survival, and in selected populations, overall survival. That matters. But it does not solve the central problem.

Treatment advances help women who already have advanced disease. They do not prevent that disease from becoming advanced in the first place. The mortality curve remains stubborn because the diagnostic curve has not moved.

This is the uncomfortable asymmetry in ovarian cancer care: we have become better oncologists but not better sentinels.

Why Symptoms and Awareness Are Not Enough

Public messaging often emphasizes “listening to your body” or recognizing symptoms such as bloating, early satiety, or pelvic discomfort. The review is careful here. These symptoms are real, but they are nonspecific and common, especially in midlife.

Relying on symptom awareness alone shifts responsibility onto women without giving them a reliable tool. It risks false reassurance when symptoms are absent and delayed evaluation when they are subtle. The evidence does not support symptom-based early detection as a population strategy.

This matters ethically. Awareness campaigns can feel empowering, but empowerment without effective action can become illusion.

Prevention Works Better Than Screening

One of the most important, and often underappreciated, points in the review is prevention.

Opportunistic salpingectomy, removal of the fallopian tubes at the time of hysterectomy or sterilization, is associated with a reduced risk of high-grade serous ovarian cancer. The biologic rationale is strong. The epidemiologic data are encouraging. Randomized trial evidence is still limited, but the signal is consistent.

This is not screening. It is risk reduction.

For women with hereditary risk, especially BRCA mutations, risk-reducing salpingo-oophorectomy remains the most effective intervention. The review is clear that timing, counseling, and long-term consequences require careful discussion, but the mortality benefit is real.

In ovarian cancer, prevention has moved further than early detection. That is unusual in oncology, and it should shape our priorities.

The Ethical Tension

There is an ethical discomfort running beneath this literature.

We are asked repeatedly why medicine cannot “just find it earlier.” The answer, supported by decades of high-quality trials, is that we have tried, and it does not work. Continuing to promise early detection without evidence risks eroding trust.

At the same time, failing to invest aggressively in prevention strategies, surgical risk reduction, and subtype-specific research reflects a different ethical failure: knowing where benefit likely lies but moving too slowly.

The review does not moralize. It does something better. It states plainly what works, what does not, and where uncertainty remains.

What Should Change

Three lessons emerge.

First, screening should not be offered outside research settings. This is not nihilism. It is honesty.

Second, prevention deserves center stage. Opportunistic salpingectomy should be discussed more routinely. Genetic risk assessment should be normalized, not treated as niche care.

Third, we must stop talking about ovarian cancer as a single entity. Research, counseling, and public communication should reflect biologic diversity, not convenience.

Closing Reflection

The tragedy of ovarian cancer is not lack of effort. It is misdirected hope.

The 2025 JAMA review by Caruso and colleagues reminds us that progress in medicine is uneven. Sometimes the ethical act is not to promise more, but to say clearly what does and does not help. Until early detection truly works, our responsibility is to prevent what we can, treat what we must, and speak honestly about both.

Modern Medicine Is Advanced, but Outcomes Tell a Different Story

Modern medicine can replace heart valves, cure many cancers, and sustain life at the edge of viability. Yet across multiple domains, women’s health outcomes lag behind what these capabilities should deliver.

Maternal morbidity remains unacceptably high. Cardiovascular disease in women is underrecognized and undertreated. Chronic pain, autoimmune disease, and mental health conditions are frequently diagnosed late.

Subscribe now

These gaps persist despite better imaging, safer medications, and more guidelines than ever before. The explanation is not a lack of technology. It is a mismatch between how medicine is organized and what women actually need across the lifespan. Progress in tools has outpaced progress in systems, incentives, and accountability.

When Evidence Exists but Is Poorly Applied

In many areas of women’s health, the problem is not absence of evidence but selective attention to it. Sex-based differences in disease presentation are well described, yet they are inconsistently taught and unevenly incorporated into practice. Cardiovascular disease remains framed in male-centric symptom models. Pregnancy-related complications have clear warning signs, yet those signs are often normalized or dismissed.

Menopause is associated with predictable physiologic changes, but clinical training still treats it as peripheral rather than central to long-term health. Evidence does not implement itself. It must be translated into workflows, decision thresholds, and follow-up standards.

When that translation fails, outcomes stagnate even as knowledge advances.

Systems That Reward Rescue Over Prevention

Health care payment and delivery systems play a decisive role in shaping women’s health outcomes. Prevention in women’s health often means time-intensive vigilance, early risk recognition, conservative use of interventions, and continuity of care. These activities are cognitively demanding and poorly reimbursed. By contrast, acute interventions, procedures, and downstream rescue are rewarded more reliably. The result is a system that reacts well to crisis but performs poorly at prevention. This dynamic is particularly harmful for women, whose conditions often evolve gradually and present with subtle early symptoms. When systems prioritize speed over continuity and volume over vigilance, preventable harm becomes normalized rather than interrogated.

Autonomy Framed Without Responsibility

Women’s health discourse frequently elevates autonomy while quietly hollowing it out. Autonomy is not protected by neutrality or by withholding professional judgment. Women are not empowered when clinicians avoid clear recommendations to appear non-directive. In practice, this shifts risk silently onto patients without acknowledging it. Ethical care requires more. It requires clinicians to explain risk honestly, to distinguish between low-risk and high-risk options, and to say so plainly. When professional responsibility is reframed as paternalism, clinicians become reluctant to counsel firmly, and women are left navigating complex medical terrain without adequate guidance. Outcomes suffer not because women choose poorly, but because systems fail to support informed decision-making.

Measurement, Equity, and the Limits of Innovation

What medicine measures shapes what it improves. Many outcomes that matter deeply to women, including pain, function, fertility, sexual health, and long-term quality of life, are difficult to quantify and therefore underweighted in quality metrics. Equity further complicates this picture. Women from marginalized communities face compounded risks due to fragmented care, implicit bias, language barriers, and limited access to preventive services.

Technology and artificial intelligence are often proposed as solutions, but tools trained on biased data or deployed without oversight can reproduce existing inequities. Innovation without accountability does not close gaps.

It widens them. Improving women’s health outcomes requires better metrics, transparent data, and systems willing to learn from failure rather than obscure it.

Closing the Gap Requires Structural Honesty

Women’s health outcomes lag not because medicine lacks capability, but because it lacks alignment. Evidence is unevenly applied. Prevention is undervalued. Autonomy is misunderstood. Measurement is incomplete. Equity is treated as aspiration rather than obligation. Closing this gap does not require new slogans or symbolic commitments. It requires structural honesty about where systems fail women and why. Women’s health will improve when vigilance is rewarded, uncertainty is named rather than smoothed over, and professional responsibility is reclaimed as a core ethical duty. Modern medicine already has many of the tools it needs. The question is whether it is willing to use them differently.